Related Experiment Video
Updated: Oct 4, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion
Wei Li1, Runfeng Gao2, Juan Zhao3
1Graduate School of Dalian Medical University, Dalian, China; Department of Cardiology, Taizhou People's Hospital, Taizhou, China.
Insights
New oral anticoagulants plus single antiplatelet therapy (NOAC + SAPT) is safe and effective after Watchman left atrial appendage occlusion (LAAC). This regimen reduced the risk of early device-related thrombosis (DRT) without increasing major bleeding or stroke events.
Area of Science:
- Cardiology
- Interventional Cardiology
- Thrombosis Research
Background:
- Atrial fibrillation (AF) patients undergoing left atrial appendage occlusion (LAAC) require effective anticoagulation.
- The optimal postoperative anticoagulation strategy after LAAC with the Watchman device remains under investigation.
Purpose of the Study:
- To compare the safety and efficacy of two postoperative anticoagulation regimens in AF patients after Watchman LAAC.
- To evaluate the incidence of ischemic stroke/TIA, major bleeding, all-cause mortality, and device-related thrombosis (DRT).
Main Methods:
- Retrospective analysis of 160 AF patients who underwent Watchman LAAC.
- Patients were divided into two groups: oral anticoagulant (OAC)/new OAC (NOAC) alone vs. NOACs + single antiplatelet therapy (SAPT).
- Multivariate regression identified predictors of early DRT.
Main Results:
- No significant differences in ischemic stroke/TIA, major bleeding, or all-cause mortality between groups.
- The NOAC + SAPT group showed a significantly lower incidence of early DRT compared to the OAC/NOAC group (P=0.048).
- Atrial blood stasis and peri-device leak were independent predictors of early DRT.
Conclusions:
- Short-term NOAC + SAPT is a safe and effective strategy post-LAAC.
- This regimen reduces the risk of early DRT compared to OAC/NOAC therapy alone.
- NOAC + SAPT did not increase short-term risks of stroke, bleeding, or mortality.
Background:
This study examined the safety and efficacy of different anticoagulation regimens in patients with atrial fibrillation (AF) after left atrial appendage occlusion (LAAC) using the Watchman closure device.
Methods:
AF patients who underwent LAAC using the Watchman closure device in the Department of Cardiology, Jiangsu Taizhou People's Hospital between March 2018 and November 2019 were retrospectively enrolled in this study. Patients were divided into two groups according to different postoperative anticoagulant regimens. One group was treated with anticoagulant therapy alone [oral anticoagulant (OAC)/new OAC (NOAC) group] and the other was given NOACs combined with single antiplatelet therapy (SPAT) (NOAC + SAPT group). The incidences of ischemic stroke/transient ischemic attack (TIA), major bleeding events, all-cause mortality, and device-related thrombosis (DRT) were recorded. Furthermore, multivariate regression was used to analyze the factors associated with the occurrence of early DRT.
Results:
A total of 160 patients, including 42 (51%) females, with a mean age of 69.13±6.14 years were enrolled in this study. The mean CHA2DS2-VASc score was 3.66±1.11 and the mean HAS-BLED score was 4.16±0.82. During the postoperative follow-up period, there were no significant differences in the incidence of ischemic stroke/TIA [hazard ratio (HR) =0.616; 95% confidence interval (CI): 0.056 to 6.818; P=0.693], major bleeding events (HR =0.520; 95% CI: 0.047 to 5.764; P=0.594) nor all-cause mortality (HR =0.579; 95% CI: 0.052 to 6.394; P=0.656) between the two groups. However, the incidence of early DRT was higher in the OAC/NOAC group compared to the NOAC + SAPT group [odds ratio (OR) =0.120; 95% CI: 0.015 to 0.984; P=0.048]. Multivariate regression confirmed that atrial blood stasis (OR =11.367; 95% CI: 1.394 to 92.687; P=0.023) and peri-device leak (OR =9.337; 95% CI: 1.623 to 53.727; P=0.012) were independent predictors of early DRT.
Conclusions:
Short-term NOAC + SAPT after LAAC did not significantly increase the incidence of major bleeding events, ischemic stroke/TIA, nor all-cause mortality compared to OAC/NOAC therapy. Not only was NOAC + SAPT therapy found to be safe and effective in short-term follow-up, but it also lowered the risk of early DRT.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiac Catheterization III: Left Heart Catheterization

